AGEN250117C10000
- 0.10
- 0.000.00%
Agenus Newsroom
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Maintains Target Price $11
Promising Potential for Agenus in Oncology: Buy Rating Reinforced by Strong CRC and Gastric Cancer Therapy Prospects
H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating
Agenus Analyst Ratings
H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating, Maintains Target Price $7
Cautious Hold Rating on Agenus Amid Strategic Realignment and Financial Challenges
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Agenus (AGEN) and SAGE Therapeutics (SAGE)
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Cuts Target Price to $11
B. Riley Adjusts Agenus Price Target to $11 From $18, Maintains Buy Rating
Promising Developments and Strategic Financing Enhance Agenus's Buy Rating Amidst Stock Volatility
Agenus Is Maintained at Neutral by HC Wainwright & Co.
Agenus Analyst Ratings
H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating, Cuts Target Price to $7
Agenus Analyst Ratings
B. Riley Adjusts Price Target on Agenus to $18 From $42, Maintains Buy Rating
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Cuts Target Price to $18
Agenus Hold Rating: Balancing Phase 2 Progress With Regulatory Challenges and Uncertainty
Jefferies Downgrades Agenus to Hold, Raises Price Target to $7
Agenus Downgraded at Baird After FDA Feedback on Cancer Drug
HC Wainwright Downgrades Agenus to Neutral From Buy, Adjusts Price Target to $9 From $40